Neoadjuvant CAPOX and bevacizumab alone for locally advanced rectal cancer: long-term results from the N-SOG 03 trial.
Akihiro TomidaKeisuke UeharaKazuhiro HiramatsuAtsuyuki MaedaEiji SakamotoYoshito OkadaYasuhiro KurumiyaGoro NakayamaMasanao NakamuraToshisada AibaMasato Naginonull nullPublished in: International journal of clinical oncology (2018)
Patients with cT4b tumor were not suitable for NAC alone. However, the long-term outcomes of the other patients were satisfactory, and NAC alone might be an option for treatment of LARC. N down-staging was likely to bring favorable PFS, even in patients with cStage III.
Keyphrases
- rectal cancer
- transcription factor
- locally advanced
- end stage renal disease
- lymph node
- ejection fraction
- computed tomography
- clinical trial
- study protocol
- peritoneal dialysis
- magnetic resonance imaging
- squamous cell carcinoma
- magnetic resonance
- radiation therapy
- pet ct
- phase iii
- genome wide analysis
- combination therapy
- replacement therapy
- open label